Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-25

Clinical Trial Update: Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA

View source ↗

Summary

The update reports on the incidence of hepatitis D relapse after discontinuation of bulevirtide in patients with chronic hepatitis D who had negative HDV RNA. I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Hepcludex (bulevirtide)

Snippet

Sponsor: Center of target therapy | Conditions: Chronic Hepatitis D | Status: COMPLETED